Vaccine evolution: from traditional shots to mrna tech & India's role in global health security

Vaccines are one of the most significant public health achievements, preventing millions of deaths annually. They work by training the body’s innate and acquired (adaptive) immunity to recognize and combat specific pathogens without causing the disease itself. This process primarily involves the humoral immune response (B-cells producing antibodies) and the cell-mediated immune response (T-cells destroying infected cells).

Fun Fact: The word “vaccine” originates from the Latin word vacca, meaning “cow.” It was coined by Edward Jenner, who observed that milkmaids infected with the mild cowpox virus were immune to the deadly smallpox.

The Evolution of Vaccine Technology

Vaccine development has progressed from using whole pathogens to employing precise genetic engineering, offering improved safety and faster production.

Traditional vs. Modern Vaccines

Mnemonic for Traditional Vaccines: L.I.S.T. A simple way to remember the four main types of traditional vaccines:

• Live-attenuated
• Inactivated
• Subunit
• Toxoid

Dynamic Update: The New Frontier of Vaccine Science

The landscape of vaccinology is rapidly changing. The urgency of the COVID-19 pandemic catalyzed platforms like mRNA vaccines, which instruct our cells to make a harmless piece of the virus, triggering an immune response.

A major recent development is the application of this technology beyond infectious diseases. In 2023-2024, companies like BioNTech and Moderna have shown promising results in clinical trials for personalized mRNA cancer vaccines, designed to train the immune system to attack a patient’s specific tumor cells.

Furthermore, in a landmark achievement for global health, the R21/Matrix-M malaria vaccine, developed by the University of Oxford and manufactured by India’s Serum Institute, received WHO prequalification in late 2023. Its rollout in African nations in 2024 marks a pivotal step in combating a disease that kills hundreds of thousands annually.

Fun Fact: mRNA vaccines are like sending a temporary “recipe” to your body’s protein-making machinery (ribosomes). The recipe tells them how to cook up a viral protein (the antigen), and once the immune system sees it, it prepares its defenses. The recipe itself is destroyed shortly after.

India: The ‘Pharmacy of the World’

India is a powerhouse in vaccine production, supplying over 60% of the world’s vaccines. Cities like Hyderabad and Pune are at the heart of this ecosystem. The country’s domestic immunization efforts are anchored by the Universal Immunization Programme (UIP), one of the largest public health programs globally.

Mission Indradhanush (IMI) was launched to accelerate immunization coverage. Its latest phase, IMI 5.0 (launched in 2023), notably expanded its focus to include children up to 5 years of age, aiming to reach “zero-dose” children who have not received any routine vaccinations.

During the COVID-19 pandemic, India’s ‘Vaccine Maitri’ initiative supplied millions of doses to countries worldwide, showcasing its capacity for vaccine diplomacy.

Global Governance and Pandemic Preparedness

International bodies like the World Health Organization (WHO) and GAVI, the Vaccine Alliance, are crucial for coordinating global immunization strategies and ensuring vaccine equity. The Immunisation Agenda 2030 (IA2030) is a global strategy to maximize the life-saving impact of vaccines.

However, the COVID-19 pandemic exposed deep inequalities. In response, WHO members are negotiating a Pandemic Accord (or treaty). As of late 2024, these negotiations face hurdles, particularly around the Pathogen Access and Benefit-Sharing (PABS) system, which aims to ensure that countries providing pathogen data receive equitable access to the resulting vaccines and treatments.

Staggering Stat: The WHO estimates that vaccines prevent 4-5 million deaths every year, making them one of the most cost-effective health interventions available.

Critical Policy Appraisal

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis

The legal framework for vaccine regulation in India is primarily governed by the Drugs and Cosmetics Act, 1940, and its rules, with the Central Drugs Standard Control Organisation (CDSCO) acting as the main regulatory body. At a policy level, the National Health Policy guides the country’s public health and immunization strategies.

UPSC Integration: Connecting the Dots

• Polity (GS-2): Health is a State Subject, but vaccine policy and pandemic management require strong cooperative federalism. The role of regulatory bodies (CDSCO) and their autonomy is a key governance topic.
• International Relations (GS-2): ‘Vaccine Maitri’ is a prime example of health diplomacy and soft power. The Pandemic Accord negotiations highlight the complexities of global governance and North-South divides.
• Economy (GS-3): The pharmaceutical industry is a “sunrise sector” for India. Issues of Intellectual Property Rights (IPR), such as the TRIPS waiver for COVID-19 vaccines, are critical economic and trade topics.

Expert Analysis: Future Impact

The future of vaccinology lies in personalization and speed. We are moving towards an era of bespoke mRNA vaccines for cancers and rapid-response platforms that can develop, test, and deploy a vaccine for a novel pathogen (“Disease X”) within 100 days. For India, maintaining its leadership in manufacturing while also investing in cutting-edge R&D will be crucial for its strategic autonomy and global standing. Geopolitically, the ability to develop and supply vaccines will be as critical as military strength in the 21st century.

Prelims Practice MCQ

Question: Which of the following vaccine types uses a genetically modified, harmless version of a different virus (e.g., an adenovirus) to deliver genetic instructions for creating an antigen to the body’s cells?

(a) Inactivated Vaccine (b) Toxoid Vaccine (c) Viral Vector Vaccine (d) Subunit Vaccine

Answer: (c) Viral Vector Vaccine Explanation: Viral vector vaccines use a modified, safe virus as a “vector” or carrier to deliver the genetic code of the target pathogen’s antigen. The body’s cells then produce this antigen, triggering an immune response. Covishield (using a chimpanzee adenovirus vector) is a classic example. Inactivated vaccines use killed pathogens, toxoid vaccines use inactivated toxins, and subunit vaccines use only specific pieces of the pathogen.

Mains Sample Question

Question: While India has earned the title ‘pharmacy of the world,’ the COVID-19 pandemic highlighted significant challenges in ensuring equitable vaccine access both domestically and globally. Critically analyze the successes and failures of India’s vaccine development and distribution strategy, suggesting measures to strengthen its pandemic preparedness for the future. (15 Marks, 250 words)

Mind Map Outline (Revision Structure)

• Vaccines & Global Health Security
  • Fundamentals of Immunity
    • Innate vs. Acquired (Adaptive) Immunity
    • Humoral Response (Antibodies) vs. Cell-Mediated Response (T-cells)
  • Evolution of Vaccine Technology
    • Traditional Vaccines (L.I.S.T. Mnemonic)
      • Live-Attenuated (e.g., Polio, MMR)
      • Inactivated (e.g., Rabies)
      • Subunit (e.g., Hepatitis B)
      • Toxoid (e.g., Tetanus, Diphtheria)
    • Modern Vaccines (Post-COVID Era)
      • mRNA Vaccines (e.g., Pfizer, Moderna)
        • Recent Application: Cancer Trials (2023-24)
      • Viral Vector Vaccines (e.g., Covishield, Sputnik V)
      • Other Platforms: DNA, Nanoparticle, Virus-Like Particles (VLP)
  • India’s Vaccine Ecosystem
    • Policy & Public Health Programs
      • Universal Immunization Programme (UIP)
      • Mission Indradhanush (IMI) & IMI 5.0 (2023)
    • Manufacturing & Diplomacy
      • Key Hubs: Hyderabad (“Vaccine Capital”), Pune
      • Regulatory Body: CDSCO (under Drugs and Cosmetics Act, 1940)
      • Soft Power: ‘Vaccine Maitri’ Initiative
  • Global Health Governance & Contemporary Issues
    • Key International Actors
      • World Health Organization (WHO)
      • GAVI, the Vaccine Alliance
    • Current Challenges & Initiatives (Post-2023)
      • WHO Pandemic Accord Negotiations (Ongoing 2024)
        • Sticking Point: Pathogen Access and Benefit-Sharing (PABS)
      • Vaccine Equity vs. Vaccine Nationalism
      • Landmark Approval: R21/Matrix-M Malaria Vaccine (2023)
  • Critical Appraisal & UPSC Focus
    • Challenges: Inequity, Hesitancy, Logistics, AMR
    • Opportunities: Rapid Tech, Disease Eradication, Economic Growth
    • UPSC Linkages: Polity (Federalism), IR (Diplomacy), Economy (IPR)